Tag: form

LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (NASDAQ: NATR) (“Nature’s Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”).

DUBLIN, June 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”), a leading provider of energy engineering, advisory, and utility solutions, today announced that all shareholder proposals were approved at the general meeting of shareholders held on June 25, 2025 (the “Annual General Meeting” or the “AGM”).

DOGP Holdings Set to Double to 4.02 Billion DOG

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

Transaction in Own Shares

Hong Kong, June 25, 2025 (GLOBE NEWSWIRE) -- Happy City Holdings Limited (Nasdaq: HCHL) (the “Company”), an established all-you-can-eat hotpot restaurant operator in Hong Kong , announced the closing of its initial public offering (the “Offering”) of 1,100,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $5.00 per Class A Ordinary Share (the “Offering Price”)

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.